Preliminary results of a phase I study: A chimeric monoclonal anti IL-6 antibody CNTO 328 in combination with docetaxel in patients with hormone refractory prostate cancer

被引：0
|
作者：
Hudes, G. R.
Nanus, D.
Qi, M.
Prabhakar, U.
Corringham, R.
Jiao, Q.
Eisenberger, M.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Cornell Univ, New York Presbyterian Hosp, New York, NY 10021 USA
[3] Centocor Inc, Malvern, PA 19355 USA
[4] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15521
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A combination of irofulven and oxaliplatin is active in patients with hormone refractory prostate cancer (HRPC) with secondary resistance to docetaxel: Phase I preliminary evidence.
    Tchen, N
    Alexandre, J
    Misset, JL
    Berthault-Cvitkovic, F
    Kahatt, C
    Benettaib, B
    Weems, G
    MacDonald, JR
    Cvitkovic, E
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9057S - 9058S
  • [22] A phase I/II study of a chimeric antibody against interleukin-6 (CNTO 328) in subjects with metastatic renal cell carcinoma
    Mulders, PF
    Debruyne, FMJ
    de Weijer, K
    Rossi, JF
    Patil, S
    Cooper, J
    Prabhakar, U
    Garay, C
    Corringham, R
    JOURNAL OF UROLOGY, 2005, 173 (04): : 380 - 380
  • [23] Zoledronic acid/docetaxel combination in hormone refractory prostate cancer patients zante study
    Facchini, G.
    Caraglia, M.
    Bruni, G. S.
    Nasti, G.
    Maiolino, P.
    Marra, M.
    Gallo, L.
    Bochicchio, A.
    Budillon, A.
    Iaffaioli, R. V.
    ANNALS OF ONCOLOGY, 2007, 18 : 64 - 64
  • [24] Phase I clinical study on docetaxel/zoledronic acid combination administered in two different sequences in hormone refractory prostate cancer patients
    Iaffaioli, R. V.
    Facchini, G.
    Caraglia, M.
    Bruni, G. S.
    Maiolino, P.
    Nasti, G.
    Marra, M.
    Addeo, S. R.
    Gallo, L.
    Budillon, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
    Di Lorenzo, Giuseppe
    Figg, William D.
    Fossa, Sophie D.
    Mirone, Vincenzo
    Autorino, Riccardo
    Longo, Nicola
    Imbimbo, Ciro
    Perdona, Sisto
    Giordano, Antonio
    Giuliano, Mario
    Labianca, Roberto
    De Placido, Sabino
    EUROPEAN UROLOGY, 2008, 54 (05) : 1089 - 1096
  • [26] Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer
    Tolcher, AW
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 67 - 70
  • [27] A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer
    Oh, WK
    Hagmann, E
    Manola, J
    George, DJ
    Gilligan, TD
    Jacobson, JO
    Smith, MR
    Kaufman, DS
    Kantoff, PW
    CLINICAL CANCER RESEARCH, 2005, 11 (01) : 284 - 289
  • [28] Phase I study of epirubicin plus docetaxel (ET) in patients (pts) with hormone refractory prostate cancer (HRPC).
    Henary, H
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 448S - 448S
  • [29] A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Lin, Amy M.
    Rini, Brian I.
    Derynck, Mika K.
    Weinberg, Vivian
    Park, Margaret
    Ryan, Charles J.
    Rosenberg, Jonathan E.
    Bubley, Glenn
    Small, Eric J.
    CLINICAL GENITOURINARY CANCER, 2007, 5 (05) : 323 - 328
  • [30] Phase II prospective trial associating a polyamine free diet and docetaxel in hormone refractory prostate cancer patients: preliminary results
    Cipolla, B.
    Havouis, R.
    Moulinoux, J. P.
    AMINO ACIDS, 2009, 37 (01) : 50 - 51
12345